Children’s National Hospital has received $96m in funding from an anonymous donor family to advance research and care for rare paediatric brain tumours.
Being one of the largest in the hospital’s history, this donation will enable Children’s National to expand its talent pool and expedite research for safer treatments.
Go deeper with GlobalData
The donation aims to elevate standards of care, improve long-term outcomes, and support children with rare brain tumours throughout their lives.
Brain tumours pose significant challenges in children, given their ongoing brain development and potential for lifelong complications from treatments.
The donor family shares a commitment to children facing difficult diagnoses and will collaborate with Children’s National to enhance leadership in this field.
The investment will drive research breakthroughs and individualised therapies, such as cellular immunotherapy, low-intensity focused ultrasound, neurosurgical innovation, and precision medicine.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn addition, it will establish comprehensive clinical care models, emphasising patient and family resilience, mental health support, neuroscience nursing, child life services, and holistic family support, from diagnosis to recovery.
Children’s National Hospital is already leading international collaborations with hospitals across North America, South America, and Europe to advance the understanding and treatment of these rare diseases through research and clinical trials.
Children’s National president and CEO Kurt Newman said: “This incredible partnership will lift up one of the nation’s top paediatric brain tumour programs into the stratosphere.
“It will immediately propel our best-in-class research and care, allowing us to bring new therapies to children with brain tumours.
“This fundamentally changes the healthcare journey and long-term outcomes for children and their families.”
